Schizophrenia-like GABAergic gene expression deficits in cerebellar Golgi cells from rats chronically exposed to low-dose phencyclidine

Neurochemistry International

Volumn 55, Issue 8, 2009, Pages 775-782

  Bullock, W Michael ^a   Bolognani, Federico ^a   Botta, Paolo ^a   Valenzuela, C Fernando ^a   Perrone Bizzozero, Nora I ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Cerebellar Golgi cells; GABA; Gene expression; Phencyclidine; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID CARRIER; 4 AMINOBUTYRIC ACID TRANSPORTER 1; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; GLUTAMATE RECEPTOR 6; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR 2; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2C; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; NEURONAL NITRIC OXIDE SYNTHASE; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENE EXPRESSION PROFILING; GOLGI COMPLEX; GRANULE CELL; INTERNEURON; LONG TERM EXPOSURE; MALE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SCHIZOPHRENIA;

ACTION POTENTIALS; ANIMALS; CEREBELLUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID ANTAGONISTS; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION REGULATION; GLUTAMATE DECARBOXYLASE; MALE; NEURAL INHIBITION; NEURONS; ORGAN CULTURE TECHNIQUES; PATCH-CLAMP TECHNIQUES; PHENCYCLIDINE; RATS; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

ANIMALIA; RATTUS;

EID: 70349971965     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.07.010     Document Type: Article

References (68)

1. Akbarian S., and Huang H.S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res. Brain Res. Rev. 52 (2006) 293-304
2. Akbarian S., Huntsman M.M., Kim J.J., Tafazzoli A., Potkin S.G., Bunney Jr. W.E., and Jones E.G. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cereb. Cortex 5 (1995) 550-560
3. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney Jr. W.E., and Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52 (1995) 258-266
4. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney Jr. W.E., and Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16 (1996) 19-30
5. Andreasen N.C., and Pierson R. The role of the cerebellum in schizophrenia. Biol. Psychiatry 64 (2008) 81-88
6. Berthele A., Platzer S., Laurie D.J., Weis S., Sommer B., Zieglgansberger W., Conrad B., and Tolle T.R. Expression of metabotropic glutamate receptor subtype mRNA (mGluR1-8) in human cerebellum. Neuroreport 10 (1999) 3861-3867
7. Bolognani F., Tanner D.C., Merhege M., Deschenes-Furry J., Jasmin B., and Perrone-Bizzozero N.I. In vivo post-transcriptional regulation of GAP-43 mRNA by overexpression of the RNA-binding protein HuD. J. Neurochem. 96 (2006) 790-801
8. Brickley S.G., Cull-Candy S.G., and Farrant M. Development of a tonic form of synaptic inhibition in rat cerebellar granule cells resulting from persistent activation of GABAA receptors. J. Physiol. 497 Pt 3 (1996) 753-759
9. Brickley S.G., Misra C., Mok M.H., Mishina M., and Cull-Candy S.G. NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites. J. Neurosci. 23 (2003) 4958-4966
10. Bullock W.M., Cardon K., Bustillo J., Roberts R.C., and Perrone-Bizzozero N.I. Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia patients. Am. J. Psychiatry 165 (2008) 1594-1603
11. Bureau I., Dieudonne S., Coussen F., and Mulle C. Kainate receptor-mediated synaptic currents in cerebellar Golgi cells are not shaped by diffusion of glutamate. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6838-6843
12. Carta M., Mameli M., and Valenzuela C.F. Alcohol enhances GABAergic transmission to cerebellar granule cells via an increase in Golgi cell excitability. J. Neurosci. 24 (2004) 3746-3751
13. Chadderton P., Margrie T.W., and Hausser M. Integration of quanta in cerebellar granule cells during sensory processing. Nature 428 (2004) 856-860
14. Cochran S.M., Kennedy M., McKerchar C.E., Steward L.J., Pratt J.A., and Morris B.J. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28 (2003) 265-275
15. De Schutter E., Vos B., and Maex R. The function of cerebellar Golgi cells revisited. Prog. Brain Res. 124 (2000) 81-93
16. Dieudonne S. Submillisecond kinetics and low efficacy of parallel fibre-Golgi cell synaptic currents in the rat cerebellum. J. Physiol. 510 Pt 3 (1998) 845-866
17. Dugue G.P., Brunel N., Hakim V., Schwartz E., Chat M., Levesque M., Courtemanche R., Lena C., and Dieudonne S. Electrical coupling mediates tunable low-frequency oscillations and resonance in the cerebellar Golgi cell network. Neuron 61 (2009) 126-139
18. Egerton A., Reid L., McGregor S., Cochran S.M., Morris B.J., and Pratt J.A. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology (Berl.) 198 (2008) 37-49
19. Fatemi S.H., Stary J.M., Earle J.A., Araghi-Niknam M., and Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. 72 (2005) 109-122
20. Feligioni M., Holman D., Haglerod C., Davanger S., and Henley J.M. Ultrastructural localisation and differential agonist-induced regulation of AMPA and kainate receptors present at the presynaptic active zone and postsynaptic density. J. Neurochem. 99 (2006) 549-560
21. Forti L., Cesana E., Mapelli J., and D'Angelo E. Ionic mechanisms of autorhythmic firing in rat cerebellar Golgi cells. J. Physiol. 574 (2006) 711-729
22. Fritschy J.M., and Panzanelli P. Molecular and synaptic organization of GABAA receptors in the cerebellum: effects of targeted subunit gene deletions. Cerebellum 5 (2006) 275-285
23. Geurts F.J., De Schutter E., and Dieudonne S. Unraveling the cerebellar cortex: cytology and cellular physiology of large-sized interneurons in the granular layer. Cerebellum 2 (2003) 290-299
24. Grunze H.C., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., and Greene R.W. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 16 (1996) 2034-2043
25. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., Uzunov D., and Costa E. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 57 (2000) 1061-1069
26. Hamann M., Rossi D.J., and Attwell D. Tonic and spillover inhibition of granule cells control information flow through cerebellar cortex. Neuron 33 (2002) 625-633
27. Heckers S., Stone D., Walsh J., Shick J., Koul P., and Benes F.M. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch. Gen. Psychiatry 59 (2002) 521-529
28. Homayoun H., and Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27 (2007) 11496-11500
29. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
30. Jentsch J.D., Redmond Jr. D.E., Elsworth J.D., Taylor J.R., Youngren K.D., and Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277 (1997) 953-955
31. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
32. Jentsch J.D., Tran A., Le D., Youngren K.D., and Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17 (1997) 92-99
33. Kalinichev M., Robbins M.J., Hartfield E.M., Maycox P.R., Moore S.H., Savage K.M., Austin N.E., and Jones D.N. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 414-422
34. Kanichay R.T., and Silver R.A. Synaptic and cellular properties of the feedforward inhibitory circuit within the input layer of the cerebellar cortex. J. Neurosci. 28 (2008) 8955-8967
35. Kondziella D., Brenner E., Eyjolfsson E.M., and Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochem. Int. 50 (2007) 291-301
36. 2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J. Neurosci. 29 (2009) 2774-2779
37. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers Jr. M.B., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51 (1994) 199-214
38. Le Meur K., Galante M., Angulo M.C., and Audinat E. Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. J. Physiol. 580 (2007) 373-383
39. Leveille F., El Gaamouch F., Gouix E., Lecocq M., Lobner D., Nicole O., and Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 22 (2008) 4258-4271
40. Lewis D.A., Cruz D.A., Melchitzky D.S., and Pierri J.N. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am. J. Psychiatry 158 (2001) 1411-1422
41. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (2005) 312-324
42. Lindahl J.S., and Keifer J. Glutamate receptor subunits are altered in forebrain and cerebellum in rats chronically exposed to the NMDA receptor antagonist phencyclidine. Neuropsychopharmacology 29 (2004) 2065-2073
43. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
44. Mathew S.S., Pozzo-Miller L., and Hablitz J.J. Kainate modulates presynaptic GABA release from two vesicle pools. J. Neurosci. 28 (2008) 725-731
45. Misra C., Brickley S.G., Farrant M., and Cull-Candy S.G. Identification of subunits contributing to synaptic and extrasynaptic NMDA receptors in Golgi cells of the rat cerebellum. J. Physiol. 524 Pt 1 (2000) 147-162
46. Mitchell S.J., and Silver R.A. Glutamate spillover suppresses inhibition by activating presynaptic mGluRs. Nature 404 (2000) 498-502
47. Morara S., Brecha N.C., Marcotti W., Provini L., and Rosina A. Neuronal and glial localization of the GABA transporter GAT-1 in the cerebellar cortex. Neuroreport 7 (1996) 2993-2996
48. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5 (2005) 101-106
49. Mouri A., Noda Y., Enomoto T., and Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem. Int. 51 (2007) 173-184
50. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 (1995) 998-1007
51. Pemberton K.E., Belcher S.M., Ripellino J.A., and Howe J.R. High-affinity kainate-type ion channels in rat cerebellar granule cells. J. Physiol. 510 Pt 2 (1998) 401-420
52. Porter R.H., Eastwood S.L., and Harrison P.J. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 751 (1997) 217-231
53. Ramnani N. The primate cortico-cerebellar system: anatomy and function. Nat. Rev. Neurosci. 7 (2006) 511-522
54. Reynolds L.M., Cochran S.M., Morris B.J., Pratt J.A., and Reynolds G.P. Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr. Res. 73 (2005) 147-152
55. Rossi D.J., Hamann M., and Attwell D. Multiple modes of GABAergic inhibition of rat cerebellar granule cells. J. Physiol. 548 (2003) 97-110
56. Rujescu D., Bender A., Keck M., Hartmann A.M., Ohl F., Raeder H., Giegling I., Genius J., McCarley R.W., Moller H.J., and Grunze H. A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol. Psychiatry 59 (2006) 721-729
57. Sah P., Hestrin S., and Nicoll R.A. Tonic activation of NMDA receptors by ambient glutamate enhances excitability of neurons. Science 246 (1989) 815-818
58. Salonen V., Kallinen S., Lopez-Picon F.R., Korpi E.R., Holopainen I.E., and Uusi-Oukari M. AMPA/kainate receptor-mediated up-regulation of GABAA receptor delta subunit mRNA expression in cultured rat cerebellar granule cells is dependent on NMDA receptor activation. Brain Res. 1087 (2006) 33-40
59. Sams-Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol. 8 (1997) 196-215
60. Sastry B.R., Morishita W., Yip S., and Shew T. GABA-ergic transmission in deep cerebellar nuclei. Prog. Neurobiol. 53 (1997) 259-271
61. Schmahmann J.D., and Sherman J.C. The cerebellar cognitive affective syndrome. Brain 121 Pt 4 (1998) 561-579
62. Simmons D.M., Arriza J.L., and Swanson L.W. A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radio-labeled single-stranded RNA probes. J. Histotechnol. 12 (1989) 169-181
63. Takayama C., and Inoue Y. Developmental expression of GABA transporter-1 and 3 during formation of the GABAergic synapses in the mouse cerebellar cortex. Brain Res. Dev. Brain Res. 158 (2005) 41-49
64. Tanaka K., Suzuki M., Sumiyoshi T., Murata M., Tsunoda M., and Kurachi M. Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat. Brain Res. 992 (2003) 239-245
65. Wall M.J. Endogenous nitric oxide modulates GABAergic transmission to granule cells in adult rat cerebellum. Eur. J. Neurosci. 18 (2003) 869-878
66. Wass C., Archer T., Palsson E., Fejgin K., Klamer D., Engel J.A., and Svensson L. Effects of phencyclidine on spatial learning and memory: nitric oxide-dependent mechanisms. Behav. Brain Res. 171 (2006) 147-153
67. Watanabe D., and Nakanishi S. mGluR2 postsynaptically senses granule cell inputs at Golgi cell synapses. Neuron 39 (2003) 821-829
68. Wiley J.L. Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition. Neuropsychopharmacology 19 (1998) 86-94